NYSE:NVRO - Nevro Stock Price, Price Target & More

$90.76 -0.79 (-0.86 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$90.76

Today's Range$90.3550 - $92.44

52-Week Range$65.00 - $97.70

Volume238,229 shs

Average Volume347,514 shs

Market Capitalization$2.75 billion

P/E Ratio-72.61

Dividend YieldN/A

Beta-0.53

About Nevro (NYSE:NVRO)

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

SymbolNYSE:NVRO

CUSIPN/A

Webwww.nevro.com

Phone650-251-0005

Debt

Debt-to-Equity Ratio0.58%

Current Ratio7.61%

Quick Ratio5.91%

Price-To-Earnings

Trailing P/E Ratio-72.61

Forward P/E Ratio-119.42

P/E GrowthN/A

Sales & Book Value

Annual Sales$326.67 million

Price / Sales8.29

Cash FlowN/A

Price / CashN/A

Book Value$8.41 per share

Price / Book10.79

Profitability

EPS (Most Recent Fiscal Year)($1.25)

Net Income$-36,650,000.00

Net Margins-11.22%

Return on Equity-15.01%

Return on Assets-8.47%

Miscellaneous

Employees676

Outstanding Shares29,840,000

How to Become a New Pot Stock Millionaire

Nevro (NYSE:NVRO) Frequently Asked Questions

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro's earnings last quarter?

Nevro (NYSE:NVRO) announced its earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The medical equipment provider had revenue of $97.96 million for the quarter, compared to analyst estimates of $96.87 million. Nevro had a negative return on equity of 15.01% and a negative net margin of 11.22%. The company's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.34) EPS. View Nevro's Earnings History.

When is Nevro's next earnings date?

Nevro is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Nevro.

What price target have analysts set for NVRO?

8 Wall Street analysts have issued 1-year target prices for Nevro's shares. Their predictions range from $83.00 to $110.00. On average, they anticipate Nevro's share price to reach $97.6250 in the next year. View Analyst Ratings for Nevro.

Who are some of Nevro's key competitors?

Some companies that are related to Nevro include Insulet (PODD), ICU Medical (ICUI), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), NuVasive (NUVA), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX) and K2M Group (KTWO).

Who are Nevro's key executives?

Nevro's management team includes the folowing people:

Mr. Rami Elghandour, Pres, CEO & Director (Age 39)
Mr. Andrew H. Galligan, Chief Financial Officer (Age 62)
Mr. Patrick Schmitz, VP of Operations (Age 58)
Mr. Doug Alleavitch, VP of Quality (Age 57)
Mr. Christofer Christoforou, VP of R&D (Age 48)

Has Nevro been receiving favorable news coverage?

Media stories about NVRO stock have been trending somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nevro earned a coverage optimism score of 0.17 on Accern's scale. They also gave news coverage about the medical equipment provider an impact score of 45.36 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $90.76.

How big of a company is Nevro?

Nevro has a market capitalization of $2.75 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]

MarketBeat Community Rating for Nevro (NVRO)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		289 (Vote Outperform)
Underperform Votes:		148 (Vote Underperform)
Total Votes:		437

MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Nevro (NYSE:NVRO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for Nevro in the last 12 months. Their average twelve-month price target is $97.6250, suggesting that the stock has a possible upside of 7.56%. The high price target for NVRO is $110.00 and the low price target for NVRO is $83.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.75	2.86	2.86	2.86
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$97.6250	$99.7143	$99.7143	$102.00
Price Target Upside:	7.56% upside	46.21% upside	46.21% upside	10.63% upside

Nevro (NYSE:NVRO) Consensus Price Target History

Price Target History for Nevro (NYSE:NVRO)

Nevro (NYSE:NVRO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/4/2018	Goldman Sachs	Initiated Coverage	Neutral -> Neutral	$83.00	Low
12/14/2017	BMO Capital Markets	Reiterated Rating	Buy	$100.00	High
11/7/2017	Canaccord Genuity	Lower Price Target	Buy	$120.00 -> $110.00	N/A
11/7/2017	Northland Securities	Reiterated Rating	Buy	$96.00	N/A
11/7/2017	Leerink Swann	Reiterated Rating	Outperform	$105.00 -> $110.00	N/A
8/8/2017	Morgan Stanley	Boost Price Target	Overweight	$87.00 -> $95.00	Medium
7/3/2017	JPMorgan Chase	Reiterated Rating	Overweight	$102.00	Low
5/14/2017	B. Riley	Downgrade	Neutral	$85.00	Low
8/11/2016	Piper Jaffray	Reiterated Rating	Overweight	$98.00 -> $112.00	N/A
8/9/2016	JMP Securities	Boost Price Target	Market Outperform	$90.00 -> $110.00	N/A
8/8/2016	Bank of America	Initiated Coverage	Buy	$100.00	N/A
7/19/2016	William Blair	Initiated Coverage	Outperform		N/A
7/12/2016	Wells Fargo	Initiated Coverage	Outperform		N/A
5/16/2016	Sterne Agee CRT	Reiterated Rating	Buy		N/A

(Data available from 4/21/2016 forward)

Nevro (NYSE:NVRO) Earnings History and Estimates Chart

Earnings by Quarter for Nevro (NYSE:NVRO)

Nevro (NYSE:NVRO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.44)
2019 EPS Consensus Estimate: ($0.14)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.34)	($0.13)	($0.24)
Q2 2018	2	($0.23)	($0.06)	($0.15)
Q3 2018	2	($0.16)	($0.03)	($0.10)
Q4 2018	1	$0.04	$0.04	$0.04
Q1 2019	2	($0.33)	$0.02	($0.16)
Q2 2019	2	($0.13)	$0.04	($0.05)
Q3 2019	2	($0.06)	$0.01	($0.03)
Q4 2019	2	$0.04	$0.14	$0.09

Nevro (NYSE NVRO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018							N/A
2/22/2018	Q4 2017	($0.14)	($0.15)	$96.87 million	$97.96 million	View	Listen
11/6/2017	Q3 2017	($0.23)	($0.21)	$80.50 million	$82.26 million	View	N/A
8/7/2017	Q2 2017	($0.29)	($0.40)	$77.75 million	$78.02 million	View	Listen
5/8/2017	Q1 2017	($0.26)	($0.50)	$68.71 million	$68.40 million	View	Listen
2/23/2017	Q416	($0.20)	($0.34)	$66.41 million	$70.50 million	View	N/A
11/7/2016	Q316	($0.39)	($0.14)	$58.05 million	$60.92 million	View	Listen
8/8/2016	Q216	($0.47)	($0.31)	$45.11 million	$55.40 million	View	N/A
5/9/2016	Q116	($0.65)	($0.33)	$33.48 million	$41.65 million	View	N/A
2/29/2016	Q415	($0.56)	($0.51)	$32.88 million	$33.10 million	View	Listen
11/9/2015	Q315	($0.75)	($0.70)	$12.51 million	$15.40 million	View	N/A
8/6/2015	Q215	($0.89)	($0.77)	$9.65 million	$11.40 million	View	N/A
5/11/2015	Q1	($0.5430)	($0.57)	$8.20 million	$9.66 million	View	Listen
3/18/2015	Q4 2014	($0.51)	($0.59)		$9.72 million	View	N/A
12/2/2014	Q3 2014		($0.48)		$8.67 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Nevro (NYSE:NVRO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Nevro (NYSE NVRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.90%

Insider Trading History for Nevro (NYSE:NVRO)

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Nevro (NYSE NVRO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2018	Wilfred E Jaeger	Director	Sell	160,542	$80.77	$12,966,977.34	1,518
3/5/2018	Wilfred E Jaeger	Director	Sell	42,116	$80.19	$3,377,282.04	1,518
3/1/2018	Andrew H. Galligan	CFO	Sell	7,000	$80.10	$560,700.00
3/1/2018	Wilfred E Jaeger	Director	Sell	10,000	$80.48	$804,800.00	1,518
2/27/2018	Wilfred E Jaeger	Director	Sell	14,458	$83.28	$1,204,062.24	1,518
11/14/2017	Andrew H Galligan	CFO	Sell	7,000	$75.11	$525,770.00
10/5/2017	Michael F Demane	Director	Sell	5,000	$93.50	$467,500.00
9/27/2017	Michael F. Demane	Director	Sell	5,000	$91.50	$457,500.00
9/14/2017	Wilfred E Jaeger	Director	Sell	16,467	$90.19	$1,485,158.73	1,518
9/13/2017	Michael F. Demane	Director	Sell	5,000	$89.50	$447,500.00
9/11/2017	Michael F. Demane	Director	Sell	25,000	$87.73	$2,193,250.00
8/24/2017	Wilfred E Jaeger	Director	Sell	52,520	$86.11	$4,522,497.20	1,518
8/21/2017	Wilfred E Jaeger	Director	Sell	40,343	$84.28	$3,400,108.04	1,518
8/16/2017	Wilfred E. Jaeger	Director	Sell	79,657	$82.74	$6,590,820.18
8/15/2017	Wilfred E. Jaeger	Director	Sell	29,665	$82.54	$2,448,549.10
8/14/2017	Andrew H. Galligan	CFO	Sell	7,000	$82.31	$576,170.00
8/14/2017	Wilfred E. Jaeger	Director	Sell	25,255	$82.40	$2,081,012.00
5/15/2017	Andrew H. Galligan	CFO	Sell	7,500	$75.30	$564,750.00
5/2/2017	Michael F Demane	Director	Sell	29,800	$96.07	$2,862,886.00	501,795
5/1/2017	Rami Elghandour	CEO	Sell	10,000	$95.03	$950,300.00
4/4/2017	Michael Enxing	VP	Sell	1,500	$93.53	$140,295.00
4/4/2017	Michael F Demane	Director	Sell	22,200	$93.39	$2,073,258.00	517,795
4/3/2017	Andrew H. Galligan	CFO	Sell	30,000	$94.46	$2,833,800.00
3/6/2017	Michael Enxing	VP	Sell	38,500	$91.01	$3,503,885.00
3/3/2017	Wilfred E Jaeger	Director	Sell	43,980	$95.03	$4,179,419.40
1/4/2017	Michael Enxing	VP	Sell	1,500	$75.88	$113,820.00
12/5/2016	Michael Enxing	VP	Sell	1,500	$76.38	$114,570.00
11/15/2016	Andrew H Galligan	CFO	Sell	7,500	$86.90	$651,750.00	33,315
10/10/2016	Rami Elghandour	CEO	Sell	3,000	$100.00	$300,000.00
10/6/2016	Michael F Demane	Director	Sell	139,514	$97.46	$13,597,034.44	532,425
10/4/2016	Michael Enxing	VP	Sell	1,500	$99.31	$148,965.00	39,463
8/22/2016	Doug Alleavitch	VP	Sell	3,000	$100.00	$300,000.00	5,961
8/22/2016	Wilfred E Jaeger	Director	Sell	154,840	$97.79	$15,141,803.60
8/17/2016	Wilfred E Jaeger	Director	Sell	155,160	$97.31	$15,098,619.60
8/15/2016	Andrew H Galligan	CFO	Sell	7,500	$97.71	$732,825.00	30,079
8/10/2016	Doug Alleavitch	VP	Sell	2,500	$95.00	$237,500.00	6,961
8/9/2016	Michael F Demane	Director	Sell	26,667	$91.50	$2,440,030.50	499,252
8/4/2016	Michael Enxing	VP	Sell	1,500	$82.06	$123,090.00	39,463
7/29/2016	Doug Alleavitch	VP	Sell	1,000	$85.00	$85,000.00	7,961
7/29/2016	Michael F Demane	Director	Sell	13,333	$84.00	$1,119,972.00	505,919
7/11/2016	Doug Alleavitch	VP	Sell	2,000	$80.00	$160,000.00	8,961
7/11/2016	Michael F Demane	Director	Sell	13,333	$79.00	$1,053,307.00	512,586
7/5/2016	Michael Enxing	VP	Sell	1,500	$75.39	$113,085.00	39,463
7/1/2016	Michael F Demane	Director	Sell	13,333	$74.00	$986,642.00	519,253
6/8/2016	Doug Alleavitch	VP	Sell	1,000	$75.00	$75,000.00	9,961
6/8/2016	Rami Elghandour	CEO	Sell	7,000	$76.59	$536,130.00	71,180
6/6/2016	Michael Enxing	VP	Sell	1,500	$73.29	$109,935.00	39,463
6/2/2016	Andre Walker	VP	Sell	4,000	$73.50	$294,000.00	4,197
6/1/2016	Doug Alleavitch	VP	Sell	500	$72.00	$36,000.00	10,961
5/18/2016	Wilfred E Jaeger	Director	Sell	112,983	$64.68	$7,307,740.44
5/16/2016	Andrew H Galligan	CFO	Sell	10,000	$64.78	$647,800.00	40,000
5/16/2016	Michael F Demane	CEO	Sell	39,999	$64.77	$2,590,735.23	525,920
5/12/2016	Rami Elghandour	President	Sell	7,000	$63.93	$447,510.00	68,024
5/4/2016	Michael Enxing	VP	Sell	1,500	$65.06	$97,590.00	38,913
4/4/2016	Michael Enxing	VP	Sell	8,767	$61.59	$539,959.53	46,180
4/1/2016	Rami Elghandour	President	Sell	7,000	$60.99	$426,930.00	71,180
1/11/2016	Andre Walker	VP	Sell	7,987	$70.75	$565,080.25	470
1/4/2016	Doug Alleavitch	VP	Sell	2,514	$66.47	$167,105.58	11,470
12/17/2015	Andre Walker	VP	Sell	13	$69.00	$897.00	470
12/7/2015	Rami Elghandour	President	Sell	3,500	$61.82	$216,370.00
12/2/2015	Andre Walker	VP	Sell	1,000	$64.00	$64,000.00	470
12/1/2015	Andre Walker	VP	Sell	8,000	$59.50	$476,000.00	470
11/30/2015	Andre Walker	VP	Sell	6,000	$58.50	$351,000.00	470
11/30/2015	Rami Elghandour	President	Sell	3,500	$60.00	$210,000.00
11/24/2015	Andre Walker	VP	Sell	1,000	$55.00	$55,000.00	470
11/23/2015	Andre Walker	VP	Sell	1,000	$54.00	$54,000.00	470
11/23/2015	Wilfred E Jaeger	Director	Sell	25,000	$53.48	$1,337,000.00
11/18/2015	Wilfred E Jaeger	Director	Sell	175,000	$52.24	$9,142,000.00
11/16/2015	Michael F Demane	CEO	Sell	26,667	$50.52	$1,347,216.84	573,941
11/13/2015	Brad Vale	Director	Buy	2,000	$50.76	$101,520.00	2,000
9/17/2015	Andre Walker	VP	Sell	4,000	$50.75	$203,000.00
9/2/2015	Michael F Demane	CEO	Sell	40,001	$45.11	$1,804,445.11	600,608
6/8/2015	& Johnson Johnson	Major Shareholder	Sell	1,010,265	$47.94	$48,432,104.10
6/8/2015	Bay City Capital Llc	Insider	Sell	491,835	$47.94	$23,578,569.90
6/8/2015	Wilfred E Jaeger	Director	Sell	393,468	$47.94	$18,862,855.92
11/12/2014	& Johnson Johnson	Major Shareholder	Buy	40,000	$18.00	$720,000.00
11/12/2014	A/S Novo	Insider	Buy	215,000	$18.00	$3,870,000.00

(Data available from 1/1/2013 forward)

Nevro (NYSE NVRO) News Headlines

Source:

Date	Headline
	Nevro (NVRO) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - April 14 at 12:53 PM
	Morgan Stanley Boosts Nevro (NVRO) Price Target to $95.00 www.americanbankingnews.com - April 12 at 5:45 PM
	Establishment Labs Appoints Jeremy Livianu as General Counsel globenewswire.com - April 12 at 9:53 AM
	Zacks Investment Research Lowers Nevro (NVRO) to Hold www.americanbankingnews.com - April 10 at 7:17 PM
	BRIEF-Nevro Corp Says CEO Rami Elghandour's FY 2017 Total Compensation Was $13.2 Mln www.reuters.com - April 8 at 10:24 AM
	$88.57 Million in Sales Expected for Nevro Corp (NVRO) This Quarter www.americanbankingnews.com - April 8 at 4:48 AM
	Investors Buy Large Volume of Call Options on Nevro (NVRO) www.americanbankingnews.com - April 6 at 7:24 AM
	Zacks: Analysts Expect Nevro Corp (NVRO) to Post -$0.34 Earnings Per Share www.americanbankingnews.com - April 6 at 3:08 AM
	Nevro (NVRO) Upgraded at Zacks Investment Research www.americanbankingnews.com - April 5 at 11:52 PM
	Nevro (NVRO) Earns Hold Rating from Analysts at Goldman Sachs www.americanbankingnews.com - April 4 at 8:04 AM
	Nevro Corp (NVRO) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - April 4 at 5:36 AM
	Nevro (NVRO) Raised to Hold at ValuEngine www.americanbankingnews.com - April 3 at 11:04 AM
	Nevro (NVRO) Raised to "C-" at TheStreet www.americanbankingnews.com - April 1 at 11:23 AM
	These medical devices offer hope for treating chronic pain without opioids www.cnbc.com - March 29 at 4:46 PM
	Mazor Robotics (MZOR) versus Nevro (NVRO) Financial Analysis www.americanbankingnews.com - March 27 at 11:24 AM
	Full-Body MRI Conditional Labeling Now Available in United States for Nevro Senza® Spinal Cord Stimulation System - PR Newswire (press release) www.prnewswire.com - March 22 at 4:51 PM
	Full-Body MRI Conditional Labeling Now Available in United States for Nevro Senza® Spinal Cord Stimulation System finance.yahoo.com - March 22 at 4:51 PM
	Nevro Corp (NVRO) Expected to Announce Quarterly Sales of $88.57 Million www.americanbankingnews.com - March 22 at 10:37 AM
	Analysts Anticipate Nevro Corp (NVRO) to Post -$0.34 EPS www.americanbankingnews.com - March 20 at 3:17 AM
	Nevro Target of Unusually High Options Trading (NVRO) www.americanbankingnews.com - March 14 at 7:29 AM
	Analyzing Nevro (NVRO) and T2 Biosystems (TTOO) www.americanbankingnews.com - March 13 at 1:18 AM
	Wilfred E. Jaeger Sells 42,116 Shares of Nevro Corp (NVRO) Stock www.americanbankingnews.com - March 7 at 6:16 PM
	Wilfred E. Jaeger Sells 160,542 Shares of Nevro Corp (NVRO) Stock www.americanbankingnews.com - March 7 at 6:16 PM
	Nevro Corp (NVRO) Position Increased by Royce & Associates LP www.americanbankingnews.com - March 6 at 10:53 AM
	Nevro Corp (NVRO) CFO Sells $560,700.00 in Stock www.americanbankingnews.com - March 5 at 6:40 PM
	Landscape Capital Management L.L.C. Has $1.98 Million Position in Nevro Corp (NVRO) www.americanbankingnews.com - March 4 at 2:29 PM
	Zacks: Brokerages Expect Nevro Corp (NVRO) Will Announce Quarterly Sales of $88.57 Million www.americanbankingnews.com - March 4 at 2:20 AM
	Nevro Corp (NVRO) Expected to Announce Earnings of -$0.34 Per Share www.americanbankingnews.com - March 2 at 11:20 PM
	Nevro Corp (NVRO) Director Sells $804,800.00 in Stock www.americanbankingnews.com - March 1 at 9:30 PM
	Nevro Corp (NVRO) Director Sells $1,204,062.24 in Stock www.americanbankingnews.com - March 1 at 9:30 PM
	Nevro Corp (NVRO) Shares Sold by Dorsey & Whitney Trust CO LLC www.americanbankingnews.com - March 1 at 3:48 PM
	Nevro (NVRO) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - February 28 at 10:52 AM
	CT Mason Has $1.52 Million Holdings in Nevro Corp (NVRO) www.americanbankingnews.com - February 26 at 4:01 PM
	Nevro Corp (NVRO) Shares Bought by OppenheimerFunds Inc. www.americanbankingnews.com - February 26 at 1:48 PM
	Wells Fargo & Company MN Cuts Holdings in Nevro Corp (NVRO) www.americanbankingnews.com - February 26 at 10:10 AM
	Leerink Swann Comments on Nevro Corp's Q4 2018 Earnings (NVRO) www.americanbankingnews.com - February 26 at 8:02 AM
	Nevro Corp (NVRO) PT Raised to $94 at Morgan Stanley www.streetinsider.com - February 23 at 5:14 PM
	Nevro (NVRO) Issues Earnings Results, Misses Expectations By $0.01 EPS www.americanbankingnews.com - February 22 at 11:10 PM
	Nevro Reports Fourth Quarter and Full Year 2017 Financial Results and Provides 2018 Outlook finance.yahoo.com - February 22 at 5:05 PM
	Nevro Corp’s (NYSE:NVRO) Earnings Declined -16.68%, But How Did It Fare Against The Industry? finance.yahoo.com - February 22 at 9:00 AM
	$97.62 Million in Sales Expected for Nevro Corp (NVRO) This Quarter www.americanbankingnews.com - February 16 at 10:28 AM
	Nevro (NVRO) Scheduled to Post Quarterly Earnings on Thursday www.americanbankingnews.com - February 15 at 2:56 AM
	Nevro Corp (NVRO) Expected to Post Earnings of -$0.14 Per Share www.americanbankingnews.com - February 14 at 11:00 AM
	Nevro to Report Operating Results for the Fourth Quarter and Full Year 2017 finance.yahoo.com - February 9 at 9:26 AM
	Leerink Swann Weighs in on Nevro Corp's FY2017 Earnings (NVRO) www.americanbankingnews.com - February 7 at 6:48 AM
	Nevro Corp (NVRO) Expected to Post Q3 2019 Earnings of $0.06 Per Share www.americanbankingnews.com - February 6 at 1:58 PM
	Nevro (NVRO) Lowered to "Sell" at ValuEngine www.americanbankingnews.com - February 4 at 7:40 PM
	Brokerages Expect Nevro Corp (NVRO) Will Announce Quarterly Sales of $97.60 Million www.americanbankingnews.com - January 30 at 6:18 AM
	Nevro Corp (NVRO) Given Average Rating of "Hold" by Brokerages www.americanbankingnews.com - January 19 at 5:52 AM
	Equities Analysts Set Expectations for Nevro Corp's FY2017 Earnings (NVRO) www.americanbankingnews.com - January 18 at 6:44 AM

Nevro (NYSE:NVRO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Nevro (NYSE:NVRO) Income Statement, Balance Sheet and Cash Flow Statement

Nevro (NYSE NVRO) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff